A 17-year-old Aboriginal girl from a remote Northern Territory community has a history of definite acute rheumatic fever at age 12, with subsequent echocardiography showing moderate rheumatic mitral regurgitation. She has no penicillin allergy and is often away from home for school. Which secondary prophylaxis regimen is most appropriate to reduce her risk of recurrent rheumatic fever and progression of rheumatic heart disease?